The Dermatology Digest

DECEMBER 18, 2024

The clinical results demonstrated that STEQEYMA and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of safety and efficacy. Lebwohl, MD, Professor and Systemn Chaior of Dermatology at Icahn School of Medicine at Mount Sinai in New York, NY. Celltrion Inc. The post U.S.

Portfolios 69

Portfolios Injections Office Safety 69

Dermatology Times

SEPTEMBER 26, 2023

Ruth Ann Vleugels, MD, and Christopher Bunick, MD, agreed that the long-term safety data for JAK inhibitors makes them preferable to systemic steroids.

Safety 87

Safety Dermatitis Treatments 87

Dermatology Times

APRIL 8, 2025

Dermatology Times' Editor in Chief Christopher Bunick, MD, PhD, discusses patient safety in the wake of AAD 2025, focusing on BPO recalls, corticosteroid risks, and JAK inhibitor innovations.

Safety 36

Safety Dermatology Innovations 36

Dermatology Times

MAY 16, 2024

Bristol Myers Squibb announced 70% of patients maintained significant improvement after 4 years with no new safety concerns.

Safety 74

Safety Sustainability 74

The Dermatology Digest

DECEMBER 29, 2024

We believe that the proposed testing techniques are appropriate methods to detect asbestos to help ensure the safety of talc-containing cosmetic products. The post Proposed FDA Rule Calls for Testing for Asbestos in Talc Cosmetic Products appeared first on The Dermatology Digest.

Cosmetic Products 74

Cosmetic Products Office Safety Dermatology 74

Dermatology Times

OCTOBER 1, 2024

After releasing promising data from several clinical trials, Burnett discussed the importance of studying efficacy and safety across diverse populations.

Safety 74

Safety Clinic 74

Dermatology Times

MARCH 9, 2025

Gold emphasized the necessity of recognizing and managing complications in aesthetic dermatology to ensure patient safety and optimal outcomes.

Dermatology 67

Dermatology Safety Management 67

Dermatology Times

NOVEMBER 2, 2023

The results from this 5-year open-label extension trial affirm the safety of dupilumab in adults with moderate to severe AD.

Safety 78

Safety Dermatitis 78

The Dermatology Digest

JANUARY 8, 2025

Medical spas in Las Vegas, NV, lack on-site physician supervision, according to a study by the the American Society for Dermatologic Surgery Association (ASDSA). The post ASDSA Study Highlights Lack of On-site Physician Supervision in Las Vegas Medical Spas appeared first on The Dermatology Digest.

Medical 36

Medical Social Media Safety Training 36

The Dermatology Digest

JULY 24, 2024

The post TDD Industry News and Views: Weekly Updates on Comings, Goings, and Other Happenings in Dermatology appeared first on The Dermatology Digest.

Dermatology 78

Dermatology Sales Marketing Safety 78

Dermatology Times

MARCH 18, 2024

Henry Lim, MD, shares insights on JAK inhibitor safety and the poster presented at the AAD Annual Meeting

Safety 74

Safety 74

Dermatology Times

APRIL 1, 2025

Gooderham continues a discussion on new data reinforcing the safety of topical delgocitinib, with minimal systemic absorption even under maximal use conditions.

Safety 58

Safety 58

Dermatology Times

MARCH 19, 2024

AI mobile apps have critical gaps in efficacy, safety, and transparency, according to a new report.

Safety 85

Safety Dermatology 85

The Dermatology Digest

DECEMBER 11, 2024

Despite disappointing efficacy, ANB032 was well tolerated with no safety signals observed, the Company reported. The ARISE-AD study evaluated the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ANB032 monotherapy in patients with moderate-to-severe AD.

Safety 36

Safety Dermatitis Therapy Dermatology 36

The Dermatology Digest

MARCH 3, 2025

” A double-blinded, randomized, placebo-controlled trial evaluated the safety and efficacy of BioRewind in 104 patients over 12-weeks. ”: The post This Week’s Hottest Drops, Launches, and Collabs appeared first on The Dermatology Digest. We are confident this innovation will redefine how we think about skin health.”

Medical Grade Skincare 74

Medical Grade Skincare Social Media Branding Skin Health 74

Dermatology Times

JANUARY 9, 2024

Experts in dermatology highlight the crucial role of setting treatment response expectations and stress the need for discussions on managing mild plaque psoriasis, highlighting the utilization of systemic therapies in this context.

Safety 77

Safety Education Therapy Management 77

The Dermatology Digest

FEBRUARY 17, 2025

Many parents expressed concerns about the health and safety of non-surgical cosmetic procedures and worried that their child would either grow to regret them or would want more in the future. Parents Weigh In appeared first on The Dermatology Digest. The post Should Teens Be Allowed to Undergo Non-surgical Cosmetic Procedures?

Social Media 57

Social Media Hair Removal Safety Surgery 57

The Dermatology Digest

FEBRUARY 18, 2025

It was very encouraging in the ReNeu trial to see that Gomekli provided deep and durable responses, with a manageable safety profile that enabled patients to stay on therapy. Gomekli demonstrated a manageable safety and tolerability profile. The post U.S

Networking 64

Networking Safety Innovations Management 64

The Dermatology Digest

MARCH 8, 2025

The research was presented as a late-breaker at the 2025American Academy of Dermatology(AAD) Annual Meeting inOrlando, FL. The Phase 3 TRuE-PN clinical trial program comprises TRuE-PN1 and TRuE-PN2 studies, which evaluate the safety and efficacy of twice-daily ruxolitinib cream 1.5% The overall safety profile of ruxolitinib cream 1.5%

Safety 36

Safety Clinic Therapy Dermatology 36

Dermatology Times

MARCH 24, 2025

Learn about CBD legality, safety, and potential dermatologic effects. CBD skin care is booming, but are patients getting real benefits?

Dermatology 41

Dermatology Legal Safety 41

The Dermatology Digest

MARCH 10, 2025

improves moderate-to-severe nail psoriasis, according to new research presented at the 2025American Academy of Dermatology(AAD) Annual Meeting in Orlando, FL. ” The post Tildrakizumab (Ilumya, Sun Pharma) Improves Moderate-to-severe Nail PsO appeared first on The Dermatology Digest.

Pharmaceutical 36

Pharmaceutical Safety Clinic Injections 36

The Dermatology Digest

FEBRUARY 6, 2025

SPECTREM is an ongoing Phase 3b, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of guselkumab in participants with low BSA (215%), moderate (Investigators Global Assessment [IGA]=3) plaque psoriasis involving 1 special sites (scalp, face, intertriginous, or genital).

Safety 36

Safety Dermatology Clinic 36

The Dermatology Digest

NOVEMBER 18, 2024

Safety data was found to be consistent with the Phase 2 FRONTIER 1 and 2 studies. ” The post PsO Pipeline Update: Icotrokinra, an Oral IL-23 Blocker, Looks Good in Topline Phase 3 Data appeared first on The Dermatology Digest. Further increases in response rates continued to be observed at week 24, with 74.1% achieving PASI-90.

Safety 36

Safety Medical Innovations Dermatology 36

The Dermatology Digest

APRIL 11, 2025

anhydrous gel is showing promise in the treatment of microcystic lymphatic malformations (microcystic LMs), according to a presentation at the 15th World Congress of Pediatric Dermatology in Buenos Aires, Argentina. Anhydrous Gel Shows Promise for Microcystic LMs appeared first on The Dermatology Digest. . s QTORIN rapamycin 3.9%

Therapy 36

Therapy Dermatology Office Clinic 36

The Dermatology Digest

JANUARY 10, 2025

This larger Phase 2b trial (n=180) will focus on optimizing dosing regimens and further assessing the safety and efficacy of CGB-500. The post AD Pipeline Watch: CAGE Bio Initiates Phase 2b Trial for CGB-500, a Topical JAK Inhibitor for Moderate to Severe AD appeared first on The Dermatology Digest.

Dermatitis 36

Dermatitis Safety Technology Dermatology 36

The Dermatology Digest

NOVEMBER 30, 2024

Lipella has received an Investigational New Drug (IND) approval for a Phase 2a multicenter dose-escalation trial evaluating the safety and efficacy of LP-10 in subjects with symptomatic OLP. Incyte is investigating the efficacy and safety of ruxolitinib cream in cutaneous lichen planus. Stay tuned.

Pharmaceutical 36

Pharmaceutical Safety Marketing Therapy 36

The Dermatology Digest

JULY 1, 2024

The FDA’s approval of PYZCHIVA is based on a totality of evidence including analytical, non-clinical and clinical data demonstrating biosimilarity to Stelara, with no clinically meaningful differences in terms of safety, purity and potency. PYZCHIVA, developed by Samsung Bioepis, will be commercialized by Sandoz in the United States.

Portfolios 74

Portfolios Safety Clinic Injections 74

Dermatology Times

OCTOBER 8, 2024

Melinda Gooderham, MSc, MD, FRCPC, emphasized the significance of the study’s results, showcasing stable laboratory parameters over a 12-week trial.

Safety 74

Safety 74

The Dermatology Digest

MARCH 17, 2025

The overall safety profile of povorcitinib is consistent with previous data. No new safety signals were observed and both doses were well tolerated. Both studies include a 12-week double-blind, placebo-controlled treatment period, followed by a 42-week extension period and 30-day safety follow-up. 75mg: 40.6% 75mg: 42.3%

Safety 36

Safety Document Clinic Therapy 36

The Dermatology Digest

MARCH 17, 2025

The multi-center, randomized, double-blind, placebo-controlled, proof-of-concept trial is designed to evaluate the safety and efficacy of EVO301 in approximately 60 adult patients with moderate-to-severe AD.

Dermatitis 36

Dermatitis Eczema Injections Safety 36

The Dermatology Digest

JANUARY 28, 2025

The primary endpoint of the proof-of-concept cohort was safety and tolerability with therapeutic activity explored using the Urticaria Activity Score (UAS)-7 at 14 weeks. AK006 was well-tolerated with a favorable safety profile. AK006 Disappoints in CSU; Company Pulls Plug appeared first on The Dermatology Digest.

Safety 36

Safety Clinic Dermatology 36

Dermatology Times

DECEMBER 23, 2024

Panelists discuss how the safety data from the Effisayil 2 trial show that spesolimab was generally well-tolerated, with most adverse events being mild-to-moderate, primarily consisting of injection site reactions, and no new safety concerns emerging during the study.

Safety 36

Safety Injections 36

The Dermatology Digest

FEBRUARY 25, 2025

This announcement follows the successful completion of a Phase I clinical trial involving 40 healthy volunteers, where ruxoprubart demonstrated promising results and a clean safety profile, with no serious adverse events reported. FDA Approves IND for Ruxoprubart in DM appeared first on The Dermatology Digest. The post U.S.

Safety 36

Safety Therapy Clinic Dermatology 36

The Dermatology Digest

OCTOBER 30, 2024

Grants of up to $35,000 will be awarded to promising projects in the field of clinical, biological or pharmacological research linked to dermatology. Ultimately, our aim is to improve public health outcomes and raise awareness about the critical importance of sun safety in our communities,” say Drs. Nahar and Huynh in a news release.

Sun Protection 36

Sun Protection Dermatology Safety Innovations 36

The Dermatology Digest

APRIL 12, 2024

Recent cases where possibly counterfeit neurotoxins in Illinois and Tennessee led to a cluster of illnesses resembling Botulism highlight the need to strengthen patient safety through increased oversight of medical care in all settings, according to the American Society for Dermatologic Surgery Association (ASDSA).

Safety 69

Safety Surgery Medical Training 69

The Dermatology Digest

JANUARY 8, 2025

Key results of the study showed: Safety: ET-02 was found to be safe and well tolerated. Eirion plans to begin a Phase 2 clinical trial (N150) in 2025 with a 6-month treatment period with the goal of confirming ET-02’s safety and efficacy. A final assessment of the subjects was made one week after the treatments ended.

Safety 36

Safety Clinic Pharmaceutical Treatments 36

The Dermatology Digest

MARCH 18, 2025

It is designed to assess the safety and efficacy of aminolevulinic acid hydrochloridePDT following the application of 1-3 tubes of product over a surface area (continuous or in patches) of approximately 80, 160 or 240cm 2.

Treatments 36

Treatments Dermatology Safety Therapy 36